• Corpus ID: 11410543

Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.

@article{Artukolu2017EfficacyOP,
  title={Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.},
  author={Bekir B. Artukoğlu and Chad E. Beyer and Adi Zuloff-Shani and E. D. Brener and Michael H. Bloch},
  journal={Pain physician},
  year={2017},
  volume={20 5},
  pages={
          353-362
        }
}
BACKGROUND Palmitoylethanolamide (PEA) is a cannabimimetic compound that has been investigated as an analgesic agent in animal models and clinical trials. OBJECTIVES We conducted a meta-analysis to examine the efficacy of PEA for treating pain in randomized, controlled trials. STUDY DESIGN Systematic review and meta-analysis. SETTING This meta-analysis examined all randomized, controlled trials involving the effect of PEA on pain score. METHODS We searched PubMed and Embase for… 

Figures from this paper

Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence

Equitably powered randomized, double-blind clinical trials are needed to deepen the domains of efficacy of add-on therapy with PEA for chronic pain and improvement in functioning, neuropathic symptoms and quality of life.

The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers—A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial

It is demonstrated that PEA has clinically relevant analgesic properties, acting on both peripheral and central mechanisms as well as in pain modulation, which is essential for differentiating therapeutic approaches and the establishment of mechanism-based therapeutic approaches.

Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study

Preliminary data show that umPEA administered for three month reduces pain intensity and the number of attacks per month in pediatric patients with migraine.

The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review

There is lesser evidence of benefit in patients with nonpain symptoms related to depression, Parkinson disease, strokes, and autism, and further research is needed to define the palliative benefits to PEA.

Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?

Available evidence suggests that there is place for micro-palmitoylethanolamide in the dietary management of chronic pain in dogs and cats, especially in the micronized and co-micronized formulations, which allow for higher bioavailability.

Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews.

A new high-quality systematic review of randomised controlled trials is needed to critically assess the clinical evidence for cannabinoids, cannabis, or CBM in pain.

Efficacy of a Combination of N-Palmitoylethanolamide, Beta-Caryophyllene, Carnosic Acid, and Myrrh Extract on Chronic Neuropathic Pain: A Preclinical Study

The rationale of using natural remedies in conjunction with classical pharmacological agents to treat chronic NP is supported, as Noxiall was efficacious also in reducing CCI-induced thermal hyperalgesia.

Increased Absorption of Palmitoylethanolamide Using a Novel Dispersion Technology System (LipiSperse)

Results indicate that by using the LipiSperse® delivery system, PEA absorption is increased above the standard formulation.

The Potential of Cannabinoid-Based Treatments in Tourette Syndrome

Clinical use for refractory patients should at the very least be restricted to adult populations, given the uncertain efficacy and risk of developmental adverse effects that cannabinoids may have in children, and the overall efficacy and safety of cannabinoid-based treatments is largely unknown.

References

SHOWING 1-10 OF 49 REFERENCES

Systematic review and meta-analysis of cannabis treatment for chronic pain.

Systematic review and meta-analysis of double-blind randomized controlled trials that compared any cannabis preparation to placebo among subjects with chronic pain suggests that cannabis treatment is moderately efficacious for treatment of chronic pain, but beneficial effects may be partially (or completely) offset by potentially serious harms.

N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica.

The addition of PEA to standard treatment shows an improvement in pain relief in patients with neuropathic pain due to lumbosciatica, and PEA was well tolerated.

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.

Amitriptyline for neuropathic pain in adults.

There was no first-tier or second-tier evidence for amitriptyline in treating any neuropathic pain condition, and limited information suggests that failure with one antidepressant does not mean failure with all.

Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome

PEA proved to be effective and safe in nerve compression syndromes, and Physicians are not always aware of PEA as a relevant and safe alternative to opioids and co-analgesics in the treatment of neuropathic pain.

Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain.

These data suggest that PEA is effective in treating TMJ inflammatory pain and modulates mast cell behavior controlling both acute and chronic inflammation.

Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials

P acetamol is ineffective in the treatment of low back pain and provides minimal short term benefit for people with osteoarthritis, and these results support the reconsideration of recommendations to use paracetamol for patients with low backPain and osteOarthritis of the hip or knee in clinical practice guidelines.

Effectiveness of the Association N-Palmitoylethanolamine and Transpolydatin in the Treatment of Primary Dysmenorrhea.

Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist.

Although further studies are needed to better characterize PEA effect, the present report represents the first evidence on the improvement of distal motor latency elicited by PEA in patients with moderate CTS, and supports the hypothesis of protection against inflammatory and neuropathic pain by P EA.